Cyan is an integrated system design company headquartered in Cambridge, with customers, staff and partners across many of the world’s largest emerging markets. It provides a communication platform that enables the measurement and control of energy consumption for smart metering and lighting. Cyan is focussed on emerging markets, where it’s low cost, low power solution provides significant customer benefits. It delivers integrated solutions to utilities, municipalities and local authorities, with customer wins to date in India, Brazil and China

Regenersis is a leading, strategic outsourcing partner to the world’s premier consumer technology brands. Regenersis has built an increasingly global network of repair centres, delivered double digit revenue and profit growth, through cross-sell related services to major OEMs and network operators. In addition, the Group has traction with its scalable, high margin Advanced Solutions offering across the mobile and set top box markets.

Rex Bionics Plc (The Rex Bionics Group) is the global technology leader in robotic walking devices (REX). Uniquely, REX® provides independent mobility to wheelchair users and other mobility impaired persons using advanced robotic technology, custom-designed electromechanical actuators, precision engineering, and specialised networking systems.

Today there are two primary REX devices available; an adjustable REX Rehab for use in rehabilitation centres, and a streamlined, fit-for-purpose REX Personal made for each individual’s specific medical and physical requirements enabling the user to perform tasks and functions previously unavailable.

Rex Bionics is a rapidly growing, exciting, innovative organisation which is proud to provide advanced robotics technology to people everywhere.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.